SCHEMBL6926549

SCHEMBL6926549

O=C(O)C1CCCN1CCCc1cccnc1

nearest known ligand 0.55

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.55
FKBP1A P62942 9/20 0.53
KDM4E B2RXH2 1/20 0.53
POLB P06746 1/20 0.53
TBXAS1 P24557 4/20 0.49
MTOR P42345 1/20 0.48
FKBP4 Q02790 1/20 0.48
FKBP5 Q13451 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1818139 0.86 ALDH1A1 (0.51) FKBP1AKDM4E
SCHEMBL2027557 0.86 ALDH1A1 (0.51) FKBP1AKDM4E
SCHEMBL7412297 0.86 ALDH1A1 (0.51) FKBP1AKDM4E
SCHEMBL1817493 0.85 KDM4E (0.67) HRH3FKBP1AKDM4EPOLB
SCHEMBL2031815 0.85 KDM4E (0.67) HRH3FKBP1AKDM4EPOLB
SCHEMBL30831505 0.82 SIGMAR1 (0.49)
SCHEMBL30831483 0.81 SIGMAR1 (0.51)
SCHEMBL5685784 0.77 SIGMAR1 (0.51) KDM4E
SCHEMBL5686080 0.77 SIGMAR1 (0.51) KDM4E
SCHEMBL1116547 0.77 ALDH1A1 (0.56) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030114492-A1 Method of using neurotrophic sulfonamide compounds HAMILTON GREGORY S (US) 2003-06-19 US disclosed
EP-1014978-A4 METHOD OF USING NEUTROPHIC SULFONAMIDE COMPOUNDS GUILFORD PHARM INC (US) 2003-05-28 EP disclosed
US-6395758-B1 VISION DEFECTS GPI NIL HOLDINGS, INC. 2002-05-28 US disclosed
US-20020037924-A1 Small molecule carbamate or urea hair growth compositions and uses GPI NIL HOLDINGS, INC. (US) 2002-03-28 US disclosed
US-6333340-B1 SULFONAMIDES WITH OXO, ESTER OR AMIDE GROUPS FOR VISION DEFECTS AND COGNITION ACTIVATORS GPI NIL HOLDINGS, INC. 2001-12-25 US disclosed
US-20010029261-A1 Small molecule sulfonamide hair growth compositions and uses GUILFORD PHARMACEUTICALS INC. 2001-10-11 US disclosed
EP-1105125-A2 USE OF SULFONAMIDES FOR TREATING VISION AND MEMORY DISORDERS GPI NIL Holdings, Inc. (US) 2001-06-13 EP disclosed
EP-1105131-A2 SMALL MOLECULE CARBAMATES OR UREAS FOR VISION AND MEMORY DISORDERS GPI NIL Holdings, Inc. (US) 2001-06-13 EP disclosed
US-6245783-B1 NERVOUS SYSTEM DISORDERS GPI NIL HOLDINGS, INC. 2001-06-12 US disclosed
US-6242468-B1 Carbamate and urea compositions and neurotrophic uses GLIAMED, INC. 2001-06-05 US disclosed
US-6194440-B1 Small molecule carbamate or urea hair growth compositions and uses GPI NIL HOLDINGS, INC. 2001-02-27 US disclosed
US-6187796-B1 ALOPECIA TREATMENT; IMMUNOPHILIN AFFINITY GPI NIL HOLDINGS, INC. 2001-02-13 US disclosed
EP-1014978-A1 METHOD OF USING NEUTROPHIC SULFONAMIDE COMPOUNDS GPI NIL Holdings, Inc. (US) 2000-07-05 EP disclosed
WO-2000009104-A2 USE OF SULFONAMIDES FOR TREATING VISION AND MEMORY DISORDERS GPI NHL HOLDINGS, INC. (US) 2000-02-24 WO disclosed
WO-2000009105-A2 SMALL MOLECULE CARBAMATES OR UREAS FOR VISION AND MEMORY DISORDERS GPI NIL HOLDINGS, INC. (US) 2000-02-24 WO disclosed
WO-1999062490-A1 SMALL MOLECULE SULFONAMIDE HAIR GROWTH COMPOSITIONS AND USES GPI NIL HOLDINGS, INC. (US) 1999-12-09 WO disclosed
WO-1999062484-A1 SMALL MOLECULE CARBAMATE OR UREA HAIR GROWTH COMPOSITIONS AND USES GPI NIL HOLDINGS, INC. (US) 1999-12-09 WO disclosed
US-5968957-A ADMINISTERING TO EFFECT NEURONAL ACTIVITY GPI NIL HOLDINGS, INC. (US) 1999-10-19 US disclosed
WO-1998035675-A1 METHOD OF USING NEUROTROPHIC SULFONAMIDE COMPOUNDS GUILFORD PHARMACEUTICALS INC. (US) 1998-08-20 WO disclosed
US-5721256-A INHIBITORS OF THE ENZYME ACTIVITY ASSOCIATED WITH IMMUNOPHILIN PROTEINS GPI NIL HOLDINGS, INC. (US) 1998-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114492-A1 Method of using neurotrophic sulfonamide compounds PRSS12, FKBP8, FKBP14 HRH3 1688/4885FKBP1A 5/4885KDM4E 4240/4885
US-20020037924-A1 Small molecule carbamate or urea hair growth compositions and uses SHH, CPS1, SLC14A1 HRH3 756/4885FKBP1A 1457/4885KDM4E 239/4885
US-20010029261-A1 Small molecule sulfonamide hair growth compositions and uses PSAP, SHH, SPTSSB HRH3 1472/4885FKBP1A 152/4885KDM4E 942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.